ampelopsin has been researched along with Diabetic Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, C; Gao, S; Li, H; Qiao, Y; Wu, G | 1 |
| Bai, X; Guo, L; Luo, Q; Tan, K | 1 |
2 other study(ies) available for ampelopsin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Ampelopsin inhibits high glucose-induced extracellular matrix accumulation and oxidative stress in mesangial cells through activating the Nrf2/HO-1 pathway.
Topics: Diabetic Nephropathies; Extracellular Matrix; Flavonoids; Glucose; Humans; Mesangial Cells; NF-E2-Related Factor 2; Oxidative Stress | 2020 |
Dihydromyricetin promotes autophagy and attenuates renal interstitial fibrosis by regulating miR-155-5p/PTEN signaling in diabetic nephropathy.
Topics: Animals; Autophagy; Cells, Cultured; Diabetic Nephropathies; Disease Models, Animal; Flavonols; MicroRNAs; PTEN Phosphohydrolase; Rats; Rats, Sprague-Dawley; Signal Transduction; Transfection | 2020 |